Author:
Modi A.,Ebeling P. R.,Lee M. S.,Min Y. K.,Mithal A.,Yang X.,Baidya S.,Sen S.,Sajjan S.
Publisher
Springer Science and Business Media LLC
Subject
Orthopedics and Sports Medicine
Reference39 articles.
1. Mithal A, Dhingra V, Lau E (2009) The Asian Audit- Epidemiology, costs and burden of osteoporosis in Asia 2009: A report of International Osteoporosis Foundation 2009.
https://www.iofbonehealth.org/sites/default/files/PDFs/Audit%20Asia/Asian_regional_audit_2009.pdf
. Accesssed 15 Feb 2015
2. Wade SW, Strader C, Fitzpatrick LA, Anthony MS, O’Malley CD (2014) Estimating prevalence of osteoporosis: examples from industrialized countries. Arch Osteoporos 9:182. doi:
10.1007/s11657-014-0182-3
3. Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209–216
4. Ringe JD, Moller G (2009) Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 30:213–221. doi:
10.1007/s00296-009-0940-5
5. Payer J, Cierny D, Killinger Z, Sulkova I, Behuliak M, Celec P (2009) Preferences of patients with post-menopausal osteoporosis treated with bisphosphonates—the VIVA II study. J Int Med Res 37:1225–1229